• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.

作者信息

Malfona Francesco, Tanasi Ilaria, Piccini Matteo, Papayannidis Cristina, Federico Vincenzo, Mancini Valentina, Roncoroni Elisa, Todisco Elisabetta, Bianchi Simona, Ciotti Giulia, Chiusolo Patrizia, Gentile Massimo, Gianfelici Valentina, Giglio Fabio, Malagola Michele, Mulé Antonino, Saraceni Francesco, Vetro Calogero, Zallio Francesco, Cappelli Luca Vincenzo, Pizzolo Giovanni, Foà Robin, Bonifacio Massimiliano, Chiaretti Sabina

机构信息

Hematology, Department of Translational and Precision Medicine, Sapienza University.

Department of Engineering for Innovation Medicine, Section of Innovation Biomedicine, Hematology Area, University of Verona.

出版信息

Haematologica. 2024 Mar 1;109(3):988-993. doi: 10.3324/haematol.2023.283684.

DOI:10.3324/haematol.2023.283684
PMID:
37794811
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10905092/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e8/10905092/13fd32e5d170/109988.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e8/10905092/13fd32e5d170/109988.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/89e8/10905092/13fd32e5d170/109988.fig1.jpg

相似文献

1
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.BH3模拟物用于复发和难治性成人急性淋巴细胞白血病：一项校园ALL真实世界研究
Haematologica. 2024 Mar 1;109(3):988-993. doi: 10.3324/haematol.2023.283684.
2
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.复发难治性急性淋巴细胞白血病中使用或不使用化疗的达雷妥尤单抗。一项回顾性观察性校园ALL研究。
Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
3
A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.复发或难治性急性淋巴细胞白血病的CD19靶向免疫疗法综述
J Oncol Pharm Pract. 2018 Sep;24(6):453-467. doi: 10.1177/1078155217713363. Epub 2017 Jun 5.
4
Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.成人复发性/难治性急性淋巴细胞白血病的治疗
Curr Oncol Rep. 2016 Jun;18(6):39. doi: 10.1007/s11912-016-0519-8.
5
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.新型药物在复发/难治性 B 细胞急性淋巴细胞白血病中的应用：blinatumomab 和 inotuzumab ozogamicin 作为一线或二线新型药物治疗复发/难治性急性淋巴细胞白血病的疗效可能相当。
Cancer. 2021 Apr 1;127(7):1039-1048. doi: 10.1002/cncr.33340. Epub 2020 Dec 1.
6
Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.在一名患有4级细胞因子释放综合征的复发/难治性急性淋巴细胞白血病患者中成功重新使用博纳吐单抗。
J Oncol Pharm Pract. 2018 Jan;24(1):67-73. doi: 10.1177/1078155216676633. Epub 2016 Oct 31.
7
Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.博纳吐单抗在一名急性淋巴细胞白血病合并严重肝功能不全患者中的成功应用。
J Oncol Pharm Pract. 2020 Jan;26(1):200-205. doi: 10.1177/1078155219829534. Epub 2019 Feb 13.
8
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.同时靶向Bcl-2和mTOR信号通路可在对BH3模拟物耐药的急性淋巴细胞白血病中引发协同凋亡。
Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.
9
Agents for refractory/relapsed acute lymphocytic leukemia in adults.成人难治性/复发性急性淋巴细胞白血病的治疗药物。
Eur Rev Med Pharmacol Sci. 2014;18(17):2465-74.
10
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.Blinatumomab 治疗中国 Ph 阴性复发/难治性 B 细胞前体急性淋巴细胞白血病成人患者的疗效和安全性：一项多中心、开放标签、单臂中国注册研究。
Hematology. 2022 Dec;27(1):917-927. doi: 10.1080/16078454.2022.2111992.

引用本文的文献

1
Notch Inhibitors and BH3 Mimetics in T-Cell Acute Lymphoblastic Leukemia.Notch抑制剂与BH3模拟物在T细胞急性淋巴细胞白血病中的应用
Int J Mol Sci. 2024 Nov 29;25(23):12839. doi: 10.3390/ijms252312839.

本文引用的文献

1
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia.基于 Venetoclax 的挽救疗法治疗成人复发/难治性急性淋巴细胞白血病。
Eur J Haematol. 2023 Sep;111(3):365-372. doi: 10.1111/ejh.14015. Epub 2023 May 31.
2
CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia.CD22低表达/Bcl-2高表达表明复发/难治性急性淋巴细胞白血病患者对奥英妥珠单抗反应不佳。
Blood Adv. 2023 Jan 24;7(2):251-255. doi: 10.1182/bloodadvances.2021006810.
3
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
在因奥英妥珠单抗和博纳吐单抗治疗失败而复发/难治的费城染色体阴性B细胞急性淋巴细胞白血病患者中，预后不佳。
Am J Hematol. 2022 Jun 1;97(6):E201-E204. doi: 10.1002/ajh.26526. Epub 2022 Mar 17.
4
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia.老年（>55岁）急性淋巴细胞白血病患者的特征与预后
Cancers (Basel). 2022 Jan 23;14(3):565. doi: 10.3390/cancers14030565.
5
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.维奈托克和纳武利尤单抗联合化疗治疗复发或难治性急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者。
Cancer Discov. 2021 Jun;11(6):1440-1453. doi: 10.1158/2159-8290.CD-20-1465. Epub 2021 Feb 16.
6
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.高危费城染色体阴性成人急性淋巴细胞白血病的化疗或异基因移植。
Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311.
7
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Venetoclax 联合化疗治疗复发或难治性 T 细胞急性淋巴细胞白血病的临床经验。
Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):212-218. doi: 10.1016/j.clml.2019.09.608. Epub 2019 Sep 30.
8
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.体外药物反应分析检测耐药急性淋巴细胞白血病中的复发性敏感性模式。
Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.
9
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.成人B前体Ph阴性复发/难治性急性淋巴细胞白血病结局的国际参考分析
Haematologica. 2016 Dec;101(12):1524-1533. doi: 10.3324/haematol.2016.144311. Epub 2016 Sep 1.
10
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.针对费城染色体阳性急性淋巴细胞白血病中的 BCL-2 和 ABL/LYN。
Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.